Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVEL Trial: GARDASIL9 After Local Treatment for CIN
NCT03979014Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Nov 2019
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in cervical intraepithelial neoplasia (CIN), sponsored by Imperial College London. Started Nov 2019; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03979014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979014.